PI3K-话题@MedSci

#PI3K#

79篇内容 | 3628人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1333238, encodeId=561e133323809, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Cell Death Dis：LINC01559激活PI3K/AKT信号通路促进胃癌的发生发展, objectType=article, longId=200456, objectId=5d0e2004568a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d0e2004568a, replyNumber=0, likeNumber=109, createdTime=2020-09-10, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d0e2004568a, moduleTitle=Cell Death Dis：LINC01559激活PI3K/AKT信号通路促进胃癌的发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d0e2004568a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333237, encodeId=a5b2133323e6b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌, objectType=article, longId=200289, objectId=3ac1200289a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ac1200289a6, replyNumber=0, likeNumber=73, createdTime=2020-09-06, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ac1200289a6, moduleTitle=Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ac1200289a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333236, encodeId=16a2133323675, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Circulation：PI3Kβ调节周细胞成熟以控制血管重塑, objectType=article, longId=199915, objectId=06d919991533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06d919991533, replyNumber=0, likeNumber=98, createdTime=2020-08-27, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06d919991533, moduleTitle=Circulation：PI3Kβ调节周细胞成熟以控制血管重塑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06d919991533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333235, encodeId=e34813332358f, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=FDA批准抗肿瘤药物PI3Kα抑制剂CYH33临床试验, objectType=article, longId=196559, objectId=e8de1965590d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8de1965590d, replyNumber=0, likeNumber=96, createdTime=2020-06-28, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8de1965590d, moduleTitle=FDA批准抗肿瘤药物PI3Kα抑制剂CYH33临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8de1965590d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333234, encodeId=a1731333234ce, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Science Signal：Rac1不依赖PI3K和GTPase介导MET驱动的锚定非依赖性细胞生长, objectType=article, longId=196410, objectId=cea0196410ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cea0196410ee, replyNumber=0, likeNumber=70, createdTime=2020-06-26, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cea0196410ee, moduleTitle=Science Signal：Rac1不依赖PI3K和GTPase介导MET驱动的锚定非依赖性细胞生长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cea0196410ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333233, encodeId=239a13332334f, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Cell Death Dis：E2F1介导DDX11转录激活通过PI3K/AKT/mTOR通路促进肝细胞癌发生发展, objectType=article, longId=194080, objectId=4ff6194080ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff6194080ed, replyNumber=0, likeNumber=81, createdTime=2020-05-14, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff6194080ed, moduleTitle=Cell Death Dis：E2F1介导DDX11转录激活通过PI3K/AKT/mTOR通路促进肝细胞癌发生发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff6194080ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333232, encodeId=5a33133323257, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止, objectType=article, longId=193716, objectId=100b193e1677, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=100b193e1677, replyNumber=0, likeNumber=84, createdTime=2020-05-09, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=100b193e1677, moduleTitle=PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=100b193e1677)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333231, encodeId=25b113332314e, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Cell Death Dis：SIK2能够通过PI3K/Akt信号增加脂肪酸及胆固醇合成促进卵巢癌生长, objectType=article, longId=188027, objectId=031318802eea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=031318802eea, replyNumber=0, likeNumber=94, createdTime=2020-02-15, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=031318802eea, moduleTitle=Cell Death Dis：SIK2能够通过PI3K/Akt信号增加脂肪酸及胆固醇合成促进卵巢癌生长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=031318802eea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333230, encodeId=baee1333230f3, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Science：PIK3CA双突变患者对PI3Kα抑制剂的敏感性增强, objectType=article, longId=182671, objectId=0fe91826e1a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fe91826e1a0, replyNumber=0, likeNumber=92, createdTime=2019-11-10, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fe91826e1a0, moduleTitle=Science：PIK3CA双突变患者对PI3Kα抑制剂的敏感性增强, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fe91826e1a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333229, encodeId=d60013332295b, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Nat Commun：PTEN-ARID4B-PI3K途径鉴定了PTEN缺陷前列腺癌对ARID4B的依赖性, objectType=article, longId=181357, objectId=87a618135e82, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87a618135e82, replyNumber=0, likeNumber=163, createdTime=2019-10-08, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87a618135e82, moduleTitle=Nat Commun：PTEN-ARID4B-PI3K途径鉴定了PTEN缺陷前列腺癌对ARID4B的依赖性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87a618135e82)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333228, encodeId=bac8133322846, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号, objectType=article, longId=180514, objectId=7f23180514e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f23180514e5, replyNumber=0, likeNumber=81, createdTime=2019-10-06, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f23180514e5, moduleTitle=Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f23180514e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333227, encodeId=ff04133322e3d, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=晚期复发难治淋巴瘤：已启动PI3Kδ特异性抑制剂HMPL-689的国际I/Ib期试验, objectType=article, longId=178808, objectId=7d1c1e8808b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d1c1e8808b5, replyNumber=0, likeNumber=73, createdTime=2019-09-06, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d1c1e8808b5, moduleTitle=晚期复发难治淋巴瘤：已启动PI3Kδ特异性抑制剂HMPL-689的国际I/Ib期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d1c1e8808b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333226, encodeId=85d01333226bc, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=BMC Anesthesiol：右美托咪定通过激活PI3K/AKT/MTOR途径抑制七氟醚麻醉诱导的神经炎症反应, objectType=article, longId=178200, objectId=6b031e8200a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b031e8200a9, replyNumber=0, likeNumber=72, createdTime=2019-08-27, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b031e8200a9, moduleTitle=BMC Anesthesiol：右美托咪定通过激活PI3K/AKT/MTOR途径抑制七氟醚麻醉诱导的神经炎症反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b031e8200a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333225, encodeId=e0ae13332250c, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, objectType=article, longId=177001, objectId=9f851e70016d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f851e70016d, replyNumber=0, likeNumber=88, createdTime=2019-08-07, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f851e70016d, moduleTitle=**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f851e70016d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333224, encodeId=62851333224cb, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=王晓稼教授：探路前方，且看mTORi和PI3Ki如何逆转内分泌耐药, objectType=article, longId=174410, objectId=b6fe1e441078, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6fe1e441078, replyNumber=0, likeNumber=79, createdTime=2019-06-30, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6fe1e441078, moduleTitle=王晓稼教授：探路前方，且看mTORi和PI3Ki如何逆转内分泌耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6fe1e441078)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333223, encodeId=ece51333223b9, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=J Recept Signal Transduct Res：地塞米松通过PI3K / Akt信号通路抑制成骨细胞的成骨, objectType=article, longId=168957, objectId=dcf916895eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcf916895eac, replyNumber=0, likeNumber=84, createdTime=2019-06-23, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcf916895eac, moduleTitle=J Recept Signal Transduct Res：地塞米松通过PI3K / Akt信号通路抑制成骨细胞的成骨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcf916895eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333222, encodeId=99971333222fb, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定, objectType=article, longId=167490, objectId=8d7f16e4907c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d7f16e4907c, replyNumber=0, likeNumber=91, createdTime=2019-06-03, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d7f16e4907c, moduleTitle=拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d7f16e4907c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333221, encodeId=ab6513332218e, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=FAKTION研究: PI3K/AKT通路抑制剂带来新希望, objectType=article, longId=167060, objectId=e32e16e06047, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e32e16e06047, replyNumber=0, likeNumber=95, createdTime=2019-05-30, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e32e16e06047, moduleTitle=FAKTION研究: PI3K/AKT通路抑制剂带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e32e16e06047)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333220, encodeId=72be133322035, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=晚期乳腺癌：诺华公司的PI3K抑制剂Piqray获FDA授权, objectType=article, longId=166798, objectId=fe2e166e985f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2e166e985f, replyNumber=0, likeNumber=78, createdTime=2019-05-27, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2e166e985f, moduleTitle=晚期乳腺癌：诺华公司的PI3K抑制剂Piqray获FDA授权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe2e166e985f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1333219, encodeId=b2c0133321944, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, objectTitle=Cancer Cell Int：通过重新激活EGFR/PI3K/AKT信号，SCD1有助于EGFR靶向治疗肺癌, objectType=article, longId=165142, objectId=53341651427b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53341651427b, replyNumber=0, likeNumber=108, createdTime=2019-04-30, rootId=0, userName=ms1292405679162969, userId=7bb22500091, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53341651427b, moduleTitle=Cancer Cell Int：通过重新激活EGFR/PI3K/AKT信号，SCD1有助于EGFR靶向治疗肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53341651427b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PI3K

2020-05-29

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Cell Death Dis：LINC01559激活PI3K/AKT信号通路促进胃癌的发生发展

2020-09-10

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Clin Cancer Res：Ribociclib+氟维司群±PI3K抑制剂治疗HR+晚期乳腺癌

2020-09-06

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Circulation：PI3Kβ调节周细胞成熟以控制血管重塑

2020-08-27

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

FDA批准抗肿瘤药物PI3Kα抑制剂CYH33临床试验

2020-06-28

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Science Signal：Rac1不依赖PI3K和GTPase介导MET驱动的锚定非依赖性细胞生长

2020-06-26

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Cell Death Dis：E2F1介导DDX11转录激活通过PI3K/AKT/mTOR通路促进肝细胞癌发生发展

2020-05-14

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

PI3Kδ抑制剂umbralisib+CD20抑制剂ublituximab用于CLL试验因疗效显著提前中止

2020-05-09

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Cell Death Dis：SIK2能够通过PI3K/Akt信号增加脂肪酸及胆固醇合成促进卵巢癌生长

2020-02-15

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Science：PIK3CA双突变患者对PI3Kα抑制剂的敏感性增强

2019-11-10

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Nat Commun：PTEN-ARID4B-PI3K途径鉴定了PTEN缺陷前列腺癌对ARID4B的依赖性

2019-10-08

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Verastem的PI3K抑制剂COPIKTRA治疗T细胞淋巴瘤，获得FDA的孤儿药称号

2019-10-06

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

晚期复发难治淋巴瘤：已启动PI3Kδ特异性抑制剂HMPL-689的国际I/Ib期试验

2019-09-06

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

BMC Anesthesiol：右美托咪定通过激活PI3K/AKT/MTOR途径抑制七氟醚麻醉诱导的神经炎症反应

2019-08-27

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

**乳腺癌PI3K抑制剂Alpelisib上市，诺华开启乳腺癌分子分型新时代

2019-08-07

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

王晓稼教授：探路前方，且看mTORi和PI3Ki如何逆转内分泌耐药

2019-06-30

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

J Recept Signal Transduct Res：地塞米松通过PI3K / Akt信号通路抑制成骨细胞的成骨

2019-06-23

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

拜耳PI3K抑制剂Aliqopa治疗惰性非霍奇金淋巴瘤，获FDA的突破性治疗指定

2019-06-03

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

FAKTION研究: PI3K/AKT通路抑制剂带来新希望

2019-05-30

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

晚期乳腺癌：诺华公司的PI3K抑制剂Piqray获FDA授权

2019-05-27

ms1292405679162969 (审核中...)

前往app查看评论内容

#PI3K#

Cancer Cell Int：通过重新激活EGFR/PI3K/AKT信号，SCD1有助于EGFR靶向治疗肺癌

2019-04-30

科室
- - 订阅+
  - 更多科室
工具
服务